Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Application Number	Priority Date	Filing Date	Title
US53706895A	1995-09-21	1995-09-21
US53706795A	1995-09-21	1995-09-21
EP96931597AEP0851925B1 (en)	1995-09-21	1996-09-20	Human growth hormone variants

Publication Number	Publication Date
DK1568772T3true DK1568772T3 (da)	2010-10-18

Family

ID=27065361

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK96931597TDK0851925T3 (da)	1995-09-21	1996-09-20	Humane Væksthormonvarianter
DK05007536.5TDK1568772T3 (da)	1995-09-21	1996-09-20	Varianter af humant væksthormon

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK96931597TDK0851925T3 (da)	1995-09-21	1996-09-20	Humane Væksthormonvarianter

Country Status (14)

Country	Link
US (4)	US5849535A (da)
EP (3)	EP0851925B1 (da)
JP (2)	JP3628333B2 (da)
AT (2)	ATE455171T1 (da)
AU (1)	AU718439B2 (da)
CA (2)	CA2658039A1 (da)
DE (5)	DE69638117D1 (da)
DK (2)	DK0851925T3 (da)
ES (2)	ES2338431T3 (da)
HK (1)	HK1012508A1 (da)
LU (1)	LU91204I2 (da)
NL (1)	NL300210I2 (da)
PT (1)	PT1568772E (da)
WO (1)	WO1997011178A1 (da)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545553A (en)*	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6753165B1 (en)*	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
WO1999003887A1 (en)*	1997-07-14	1999-01-28	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
US7153943B2 (en)	1997-07-14	2006-12-26	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en)	1997-07-14	2008-03-27	Bolder Biotechnology, Inc.	Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en)*	1997-07-14	2007-09-18	Bolder Biotechnology, Inc.	Cysteine variants of alpha interferon-2
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
US6639050B1 (en)	1997-07-21	2003-10-28	Ohio University	Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en)	1997-07-21	2008-05-27	Ohio University	Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6570062B1 (en)*	1997-07-21	2003-05-27	Ohio University	Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6451986B1 (en)	1998-06-22	2002-09-17	Immunex Corporation	Site specific protein modification
US20070212422A1 (en)*	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
US6696063B1 (en)*	1998-12-30	2004-02-24	Applied Research Systems Ars Holding N.V.	Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US8288126B2 (en)	1999-01-14	2012-10-16	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
AU2008202371B2 (en)*	1999-01-14	2012-08-02	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
WO2000068385A2 (en)*	1999-05-12	2000-11-16	Xencor, Inc.	Novel nucleic acids and proteins with growth hormone activity
US6946265B1 (en)	1999-05-12	2005-09-20	Xencor, Inc.	Nucleic acids and proteins with growth hormone activity
AT408721B (de)	1999-10-01	2002-02-25	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung enthaltend ein antigen
EP1226173A1 (en)*	1999-10-07	2002-07-31	Maxygen Aps	Single-chain antagonist polypeptides
DE10005301A1 (de)*	2000-02-07	2001-08-09	Trutnau Hans Heinrich	Multi-Schritt-Kinetik molekularer Interaktionen als analytisches Mess- und Auswerte-Verfahren
GB0011459D0 (en)*	2000-05-12	2000-06-28	Univ Wales Medicine	Sequences
AU5649901A (en)*	2000-05-12	2001-11-20	Univ Wales Medicine	Method for detecting growth hormone variations in humans, the variations and their uses
JP4873818B2 (ja)*	2000-05-16	2012-02-08	ボルダーバイオテクノロジー，インコーポレイテッド	遊離システイン残基を含有するタンパク質をリフォールディングする方法
WO2001096565A2 (en)	2000-06-16	2001-12-20	Asterion Limited	Binding agents: chimeric ligand/receptor proteins
US20080194022A1 (en)*	2000-08-03	2008-08-14	Clarke Michael F	Isolation and use of solid tumor stem cells
US6984522B2 (en)*	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
US8044259B2 (en)	2000-08-03	2011-10-25	The Regents Of The University Of Michigan	Determining the capability of a test compound to affect solid tumor stem cells
CA2418960A1 (en)	2000-08-07	2002-02-14	Inhale Therapeutic Systems, Inc.	Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
AU1384302A (en)*	2000-11-10	2002-05-21	Proteopharma Aps	Apolipoprotein analogues
AU2002219021A1 (en)*	2001-01-11	2002-07-24	Maxygen Aps	Variant growth hormone molecules conjugated with macromolecular compounds
US20060183197A1 (en)*	2001-01-11	2006-08-17	Andersen Kim V	Variant growth hormone molecules conjugated with macromolecules compounds
US7060675B2 (en)*	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US6867183B2 (en)*	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6713452B2 (en)	2001-06-04	2004-03-30	Nobex Corporation	Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en)	2001-06-04	2010-05-11	Biocon Limited	Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en)	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en)*	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en)*	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1402073B1 (en)*	2001-06-05	2007-02-14	Auckland Uniservices Limited	Methods and compositions for assessment of pulmonary function and disorders
CA3009793A1 (en)	2001-06-14	2002-12-27	The Regents Of The University Of California	Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
US7196059B2 (en)*	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20040186051A1 (en)	2001-10-02	2004-09-23	Kelley Robert F	Apo-2 ligand variants and uses thereof
US6908963B2 (en)*	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7399613B2 (en)*	2001-10-10	2008-07-15	Neose Technologies, Inc.	Sialic acid nucleotide sugars
US7795210B2 (en)	2001-10-10	2010-09-14	Novo Nordisk A/S	Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en)	2001-10-10	2011-08-30	Novo Nordisk A/S	Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en)*	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
US7157277B2 (en)	2001-11-28	2007-01-02	Neose Technologies, Inc.	Factor VIII remodeling and glycoconjugation of Factor VIII
EP2279753B1 (en)*	2001-10-10	2015-09-16	Novo Nordisk A/S	Remodeling and glycoconjugation of peptides
US7696163B2 (en)	2001-10-10	2010-04-13	Novo Nordisk A/S	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20040161802A1 (en)*	2001-10-30	2004-08-19	Applied Molecular Evolution	Methods for producing and improving therapeutic potency of binding polypeptides
JP2005508650A (ja)*	2001-11-09	2005-04-07	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	Ｇｈ−１における一塩基多型
US20050233417A1 (en)*	2001-11-12	2005-10-20	Cooper David N	Growth hormone variations in humans and their uses
US20030171285A1 (en)*	2001-11-20	2003-09-11	Finn Rory F.	Chemically-modified human growth hormone conjugates
EP1453859A2 (en)*	2001-11-20	2004-09-08	Pharmacia Corporation	Chemically-modified human growth hormone conjugates
US7473680B2 (en)	2001-11-28	2009-01-06	Neose Technologies, Inc.	Remodeling and glycoconjugation of peptides
GB2384001B (en)*	2001-12-14	2004-02-04	Asterion Ltd	Chimeric growth hormone-growth hormone receptor proteins
WO2003105768A2 (en)	2002-06-13	2003-12-24	Nobex Corporation	Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
MXPA04012496A (es)	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
JP4574350B2 (ja)	2002-06-24	2010-11-04	ジェネンテック，インコーポレイテッド	Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
US20040048315A1 (en)*	2002-08-28	2004-03-11	Pharmacia Corporation	Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
US20040121407A1 (en)*	2002-09-06	2004-06-24	Elixir Pharmaceuticals, Inc.	Regulation of the growth hormone/IGF-1 axis
US7611700B2 (en)*	2002-09-09	2009-11-03	Hanall Pharmaceuticals, Co., Ltd.	Protease resistant modified interferon alpha polypeptides
MXPA05003121A (es)*	2002-09-20	2005-06-22	Pharmacia Corp	Procedimiento para disminuir los niveles de agregados de proteina polietilenglicosilada.
CN1703421B (zh)*	2002-09-20	2010-06-23	法玛西亚公司	降低peg化蛋白的聚集体水平的方法
TWI281864B (en)*	2002-11-20	2007-06-01	Pharmacia Corp	N-terminally monopegylated human growth hormone conjugates and process for their preparation
NZ525314A (en)*	2002-12-19	2005-02-25	Univ Cardiff	Method and kit for diagnosing growth hormone dysfunction by determining SNP haplotypes of the proximal promoter region of the gene GH1
JP4686361B2 (ja)*	2002-12-31	2011-05-25	アルタスファーマシューティカルズインコーポレイテッド	ヒト成長ホルモンの結晶およびその調製方法
US7803777B2 (en)	2003-03-14	2010-09-28	Biogenerix Ag	Branched water-soluble polymers and their conjugates
WO2006127896A2 (en)*	2005-05-25	2006-11-30	Neose Technologies, Inc.	Glycopegylated factor ix
US7691603B2 (en)*	2003-04-09	2010-04-06	Novo Nordisk A/S	Intracellular formation of peptide conjugates
US8791070B2 (en)	2003-04-09	2014-07-29	Novo Nordisk A/S	Glycopegylated factor IX
JP4674702B2 (ja)	2003-04-09	2011-04-20	バイオジェネリクスエージー	グリコペギレ−ション法およびその方法により生成されたタンパク質／ペプチド
WO2004090135A2 (en)*	2003-04-09	2004-10-21	Asterion Limited	Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol
US20060252120A1 (en)*	2003-05-09	2006-11-09	Kieliszewski Marcia J	Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
MXPA05011832A (es)	2003-05-09	2006-02-17	Neose Technologies Inc	Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
JP2007516693A (ja)*	2003-06-09	2007-06-28	ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン	癌の治療および診断のための組成物および方法
GB0315182D0 (en)*	2003-06-28	2003-08-06	Asterion Ltd	Cytokine variant polypeptides
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
GB0326632D0 (en)	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
US20080305992A1 (en)*	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
US8633157B2 (en)	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
US7842661B2 (en)	2003-11-24	2010-11-30	Novo Nordisk A/S	Glycopegylated erythropoietin formulations
MXPA06005732A (es)*	2003-11-24	2006-08-17	Neose Technologies Inc	Eritropoyetina glucopegilada.
US20080318850A1 (en)*	2003-12-03	2008-12-25	Neose Technologies, Inc.	Glycopegylated Factor Ix
US7956032B2 (en)*	2003-12-03	2011-06-07	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en)*	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
KR101237884B1 (ko)*	2003-12-03	2013-02-27	바이오제너릭스 에이지	글리코 peg화 과립구 콜로니 자극인자
US7338933B2 (en)*	2004-01-08	2008-03-04	Neose Technologies, Inc.	O-linked glycosylation of peptides
WO2005069845A2 (en)*	2004-01-14	2005-08-04	Ohio University	Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
MXPA06008209A (es)	2004-01-21	2006-08-31	Novo Nordisk As	Conjugacion de peptidos mediada por transglutaminasa.
JP2007519422A (ja)	2004-02-02	2007-07-19	アンブレツクス・インコーポレイテツド	修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
JP2007526455A (ja)*	2004-02-03	2007-09-13	ザリージェンツオブザユニバーシティオブミシガン	癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
US20090203589A1 (en)*	2004-02-09	2009-08-13	Pfizer Inc.	Chemically modified human growth hormone receptor antagonist conjugates
US20100028995A1 (en)*	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
EP1751177A4 (en)	2004-04-19	2008-07-16	Univ Ohio	CROSSLINKABLE GLYCOPROTEINS AND METHODS OF MAKING THE SAME
CN106434833A (zh)	2004-05-23	2017-02-22	杰勒德·M·豪斯	Theramutein调节剂
US7820409B2 (en)*	2004-06-23	2010-10-26	Usv, Ltd.	Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera
CA2601716C (en)	2004-06-25	2011-05-31	Board Of Regents, The University Of Texas System	Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
US20080300173A1 (en)	2004-07-13	2008-12-04	Defrees Shawn	Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2005269753B2 (en)	2004-07-19	2011-08-18	Biocon Limited	Insulin-oligomer conjugates, formulations and uses thereof
MX2007001180A (es)*	2004-07-26	2007-04-13	Asterion Ltd	Enlazantes.
US7597884B2 (en)	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
EP1799249A2 (en)	2004-09-10	2007-06-27	Neose Technologies, Inc.	Glycopegylated interferon alpha
JP2008516621A (ja)*	2004-10-18	2008-05-22	ノボノルディスクアクティーゼルスカブ	成長ホルモン結合体
DK2586456T3 (da)	2004-10-29	2016-03-21	Ratiopharm Gmbh	Omdannelse og glycopegylering af fibroblast vækstfaktor (FGF)
US7998930B2 (en)*	2004-11-04	2011-08-16	Hanall Biopharma Co., Ltd.	Modified growth hormones
JP5110880B2 (ja)*	2004-11-18	2012-12-26	テルモ株式会社	医薬組成物、製剤および組み合わせ製剤
CA2590462C (en)	2004-12-22	2017-02-28	Ambrx, Inc.	Methods for expression and purification of recombinant human growth hormone
ATE542920T1 (de)*	2004-12-22	2012-02-15	Ambrx Inc	Modifiziertes menschliches wachstumshormon
EP1833993A4 (en)	2004-12-22	2009-07-22	Ambrx Inc	HUMAN GROWTH HORMONE FORMULATIONS COMPRISING AN AMINO ACID CODED NON-NATURALLY
EP1838332A1 (en)*	2005-01-06	2007-10-03	Neose Technologies, Inc.	Glycoconjugation using saccharyl fragments
AU2006203792B2 (en)	2005-01-10	2011-11-03	Ratiopharm Gmbh	Glycopegylated Granulocyte Colony Stimulating Factor
US20060188498A1 (en)	2005-02-18	2006-08-24	Genentech, Inc.	Methods of using death receptor agonists and EGFR inhibitors
US20090247421A1 (en)*	2005-03-23	2009-10-01	Egisto Boschetti	Diverse chemical libraries bound to small particles with paramagnetic properties
CN101512013A (zh)*	2005-03-23	2009-08-19	生物-拉德实验室公司	与具有顺磁性质的小颗粒相连接的各种化学库
CA2602951A1 (en)*	2005-03-23	2006-09-28	Bio-Rad Laboratories, Inc.	Diverse chemical libraries bound to small particles with paramagnetic properties
EP1861125A2 (en)*	2005-03-23	2007-12-05	Nektar Therapeutics Al, Corporation	Conjugates of an hgh moiety and peg derivatives
EP1866427A4 (en)*	2005-03-30	2010-09-01	Novo Nordisk As	METHOD OF MANUFACTURING PEPTIDES PRODUCED IN INSECT CELL LINES
US9187546B2 (en)	2005-04-08	2015-11-17	Novo Nordisk A/S	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CN101163505A (zh)*	2005-04-13	2008-04-16	伊拉斯谟大学鹿特丹医药中心	使用gh拮抗剂和生长抑素激动剂的治疗方法
AU2006244683A1 (en)*	2005-05-10	2006-11-16	Synergenz Bioscience Limited	Methods and compositions for assessment of pulmonary function and disorders
CA2608161A1 (en)*	2005-05-19	2006-11-23	Synergenz Bioscience Limited	Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
EP1888779A4 (en)*	2005-05-20	2009-06-10	Synergenz Bioscience Ltd	METHOD FOR THE ANALYSIS OF POLYMORPHISMS AND USES THEREOF
US8431110B2 (en)	2005-05-23	2013-04-30	Hmi Medical Innovations, Llc.	Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
WO2006135886A2 (en)*	2005-06-13	2006-12-21	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
US7576053B2 (en)	2005-06-13	2009-08-18	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders
WO2007008708A2 (en)*	2005-07-08	2007-01-18	Ohio University	Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
MX2008002395A (es)*	2005-08-19	2008-03-18	Neose Technologies Inc	Factor vii y factor viia glicopegilados.
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007041614A2 (en)*	2005-10-03	2007-04-12	Bolder Biotechnology, Inc.	Long acting vegf inhibitors and methods of use
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja)*	2005-10-31	2013-01-23	ザリージェンツオブザユニバーシティオブミシガン	癌を処置および診断するための組成物および方法
ME02226B (me)	2005-10-31	2016-02-20	Oncomed Pharm Inc	Sastavi i postupci za dijagnozu i tretman raka
US20090048440A1 (en)	2005-11-03	2009-02-19	Neose Technologies, Inc.	Nucleotide Sugar Purification Using Membranes
US20090275070A1 (en)	2005-11-23	2009-11-05	Housey Gerard M	Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators
US20130172274A1 (en)*	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1976551A4 (en)*	2005-12-23	2009-12-30	Altus Pharmaceuticals Inc	COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
GB0602897D0 (en)*	2006-02-13	2006-03-22	Jagotec Ag	Improvements In Or Relating To Dry Powder Inhaler Devices
WO2007100640A2 (en)*	2006-02-21	2007-09-07	The Regents Of The University Of Michigan	Growth hormone receptor antagonist cancer treatment
GB0606946D0 (en)*	2006-04-06	2006-05-17	Asterion Ltd	Polypeptide antagonist
US7534595B2 (en)*	2006-06-12	2009-05-19	Biomarin Pharmaceutical Inc.	Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en)	2006-06-12	2009-05-12	Biomarin Pharmaceutical Inc.	Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20080064039A1 (en)*	2006-07-06	2008-03-13	Pienkos Philip T	Dominant negative ligand drug discovery system
US20080248959A1 (en)*	2006-07-21	2008-10-09	Neose Technologies, Inc.	Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja)*	2006-10-03	2010-02-25	ノヴォノルディスクアー／エス	ポリペプチドコンジュゲートの精製方法
MX2009003470A (es)*	2006-10-04	2009-04-14	Novo Nordisk As	Azucares y glicopeptidos pegilados enlazados a glicerol.
US20080207487A1 (en)*	2006-11-02	2008-08-28	Neose Technologies, Inc.	Manufacturing process for the production of polypeptides expressed in insect cell-lines
GB0622818D0 (en)*	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
EP2102355B1 (en)*	2006-12-14	2016-03-02	Bolder Biotechnology, Inc.	Long acting proteins and peptides and methods of making and using the same
GB0625303D0 (en)*	2006-12-19	2007-01-24	Jagotec Ag	Improvements in and relating to metered dose inhalers
WO2008092002A2 (en)*	2007-01-24	2008-07-31	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing pancreatic cancer
JP2010523582A (ja)	2007-04-03	2010-07-15	バイオジェネリクスアクチェンゲゼルシャフト	グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
US20090053167A1 (en)*	2007-05-14	2009-02-26	Neose Technologies, Inc.	C-, S- and N-glycosylation of peptides
CA2690611C (en)	2007-06-12	2015-12-08	Novo Nordisk A/S	Improved process for the production of nucleotide sugars
US7560263B2 (en)*	2007-08-17	2009-07-14	Biomarin Pharmaceutical Inc.	Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8207112B2 (en)	2007-08-29	2012-06-26	Biogenerix Ag	Liquid formulation of G-CSF conjugate
EP2195333A1 (en)*	2007-09-12	2010-06-16	Anaphore, Inc.	Hsp70-based treatment for autoimmune diseases
GB0719818D0 (en)*	2007-10-11	2007-11-21	Asterion Ltd	Growth hormone fusion polypeptides
ES2664822T3 (es)	2007-10-16	2018-04-23	Biocon Limited	Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
EP2225269A2 (en)*	2007-11-09	2010-09-08	Anaphore, Inc.	Fusion proteins of mannose binding lectins for treatment of disease
US9938333B2 (en)	2008-02-08	2018-04-10	Ambrx, Inc.	Modified leptin polypeptides and their uses
JP5619630B2 (ja)	2008-02-27	2014-11-05	ノボ・ノルデイスク・エー／エス	結合型第ｖｉｉｉ因子分子
CN105727261A (zh)	2008-06-27	2016-07-06	杜克大学	包含弹性蛋白样肽的治疗剂
US20110201022A1 (en)	2008-07-30	2011-08-18	Biomarin Pharmaceutical Inc.	Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP2323694A1 (en)*	2008-08-06	2011-05-25	Novo Nordisk Health Care AG	Conjugated proteins with prolonged in vivo efficacy
ES2663536T3 (es)	2008-09-26	2018-04-13	Oncomed Pharmaceuticals, Inc.	Agentes que se unen a receptores frizzled y usos de los mismos
AU2009303304A1 (en)	2008-10-10	2010-04-15	Anaphore, Inc.	Polypeptides that bind TRAIL-RI and TRAIL-R2
AU2010207725B2 (en)	2009-01-22	2015-06-11	Novo Nordisk Health Care Ag	Stable growth hormone compounds
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
LT2393828T (lt)	2009-02-03	2017-01-25	Amunix Operating Inc.	Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
US8680050B2 (en)	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US8445953B2 (en)	2009-07-08	2013-05-21	Taiwan Semiconductor Manufacturing Company, Ltd.	Structure for flash memory cells
CN102612376A (zh)	2009-08-06	2012-07-25	诺沃-诺迪斯克保健股份有限公司	具有延长的体内功效的生长激素
CA2777162A1 (en)*	2009-10-09	2011-04-14	Anaphore, Inc.	Polypeptides that bind il-23r
US20110086806A1 (en)*	2009-10-09	2011-04-14	Anaphore, Inc.	Polypeptides that Bind IL-23R
EP2332929A1 (en)	2009-11-25	2011-06-15	ArisGen SA	Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
SI2525834T1 (sl)	2010-01-22	2019-10-30	Novo Nordisk Healthcare Ag	Rastni hormoni s podaljšano in vivo učinkovitostjo
MX338357B (es)	2010-01-22	2016-04-13	Novo Nordisk Healthcare Ag	Compuestos estables de la hormona de crecimiento.
EP4062928A3 (en)	2010-02-04	2022-11-30	BioMarin Pharmaceutical Inc.	Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
CA2794674A1 (en)	2010-04-01	2011-10-06	Oncomed Pharmaceuticals, Inc.	Frizzled-binding agents and uses thereof
ES2632348T3 (es)	2010-04-28	2017-09-12	University Of Southern California	Déficit de receptores de la hormona del crecimiento como causa de una reducción significativa de la señalización pro-envejecimiento, del cáncer y de la diabetes
EP2595661A1 (en)	2010-07-22	2013-05-29	Novo Nordisk Health Care AG	Growth hormone conjugates
EP2446898A1 (en)	2010-09-30	2012-05-02	Laboratorios Del. Dr. Esteve, S.A.	Use of growth hormone to enhance the immune response in immunosuppressed patients
CA2834776A1 (en)	2011-05-03	2012-11-08	Genentech, Inc.	Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
EP2526971A1 (en)	2011-05-25	2012-11-28	ArisGen SA	Mucosal delivery of drugs
AU2013214698B2 (en)	2012-02-03	2017-02-16	Antisense Therapeutics Ltd	Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
WO2013119800A1 (en)	2012-02-07	2013-08-15	Massachusetts Institute Of Technology	Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
EP2911691B1 (en)	2012-10-23	2018-10-10	OncoMed Pharmaceuticals, Inc.	Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CA2899353A1 (en)	2013-02-04	2014-08-07	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a wnt pathway inhibitor
EP2970506A1 (en)*	2013-03-11	2016-01-20	Novo Nordisk Health Care AG	Growth hormone compounds
CN105229035A (zh)*	2013-03-11	2016-01-06	诺和诺德保健股份有限公司	生长激素化合物
US9168300B2 (en)	2013-03-14	2015-10-27	Oncomed Pharmaceuticals, Inc.	MET-binding agents and uses thereof
US9724396B2 (en)	2013-03-15	2017-08-08	Massachusetts Institute Of Technology	Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2014166836A1 (en)	2013-04-05	2014-10-16	Novo Nordisk A/S	Growth hormone compound formulation
BR112016002845A2 (pt)	2013-08-12	2017-09-12	Genentech Inc	composições e métodos para tratar condições associadas ao complemento
BR112016025312A2 (pt)	2014-05-01	2017-10-17	Genentech Inc	variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
CN104693433B (zh)*	2015-02-04	2017-06-06	国家纳米科学中心	一种聚乙二醇化氨磷汀、制备方法及其用途
US10317418B2 (en)	2015-02-24	2019-06-11	Massachusetts Institute Of Technology	Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
CN107743494B (zh)	2015-06-02	2022-04-29	诺和诺德股份有限公司	具有极性重组延伸体的胰岛素
MA43348A (fr)	2015-10-01	2018-08-08	Novo Nordisk As	Conjugués de protéines
EP3368074A2 (en)	2015-10-30	2018-09-05	Hoffmann-La Roche AG	Anti-factor d antibodies and conjugates
JP2018536650A (ja)	2015-10-30	2018-12-13	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体変異体コンジュゲート及びその使用
GB201520021D0 (en)	2015-11-13	2015-12-30	Asterion Ltd	Fusion polypeptide
WO2018185131A2 (en)	2017-04-05	2018-10-11	Novo Nordisk A/S	Oligomer extended insulin-fc conjugates
WO2019125002A1 (ko)*	2017-12-20	2019-06-27	(주)알테오젠	신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
KR102167827B1 (ko)*	2017-12-20	2020-10-20	주식회사 알테오젠	신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
WO2019211842A1 (en)*	2018-04-30	2019-11-07	Opko Biologics Ltd.	Long-acting human growth hormone-antagonists and methods of producing the same
CA3141128A1 (en)	2019-06-17	2020-12-24	Molecular Technologies Laboratories Llc	Therapeutic pegylated growth hormone antagonists
JP2023519213A (ja)	2020-03-24	2023-05-10	ジェネンテック，インコーポレイテッド	Ｔｉｅ２結合剤および使用方法
AU2023314508A1 (en)	2022-07-29	2024-11-14	University Of Rochester	Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone
TW202448921A (zh)	2023-05-12	2024-12-16	丹麥商諾佛儂迪克股份有限公司	長效生長激素受體拮抗劑及其用途
KR20240172522A (ko)*	2023-06-01	2024-12-10	(주)알테오젠	지속형 호르몬 수용체 길항제의 생산 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3853832A (en)*	1971-04-27	1974-12-10	Harmone Res Foundation	Synthetic human pituitary growth hormone and method of producing it
US3853833A (en)*	1971-04-27	1974-12-10	Hormone Res Foundation	Synthetic human growth-promoting and lactogenic hormones and method of producing same
US4880910A (en)*	1981-09-18	1989-11-14	Genentech, Inc.	Terminal methionyl bovine growth hormone and its use
US4446235A (en)*	1982-03-22	1984-05-01	Genentech, Inc.	Method for cloning human growth hormone varient genes
US4670393A (en)*	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
US4665160A (en)*	1982-03-22	1987-05-12	Genentech, Inc.	Novel human growth hormone like protein HGH-V encoded in the human genome
US4699897A (en)*	1983-06-04	1987-10-13	Amgen	Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (en)*	1983-07-15	1992-01-15	Bio- Technology General Corp	Method for preparing of polypeptid with superoxiddismutasne activitty
US4888286A (en)*	1984-02-06	1989-12-19	Creative Biomolecules, Inc.	Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
JPH01502640A (ja)*	1987-03-12	1989-09-14	アムジエン・インコーポレーテツド	ウシ成長ホルモン類似体
ATE84313T1 (de)*	1987-04-02	1993-01-15	Genentech Inc	Substratunterstuetzte katalyse.
US5223409A (en)*	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0768377A1 (en)*	1988-09-02	1997-04-16	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
CA2001774C (en)*	1988-10-28	2001-10-16	James A. Wells	Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5534617A (en)*	1988-10-28	1996-07-09	Genentech, Inc.	Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0441889A1 (fr)*	1988-11-07	1991-08-21	Commission des Communautés Européennes	Hormone de croissance humaine modifiee
WO1990008823A1 (en)*	1989-01-31	1990-08-09	The Upjohn Company	Somatotropin analogs
US5350836A (en)*	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
GB9015198D0 (en)*	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ES2113940T3 (es)*	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
EP0659213A1 (en)*	1991-05-01	1995-06-28	Ohio University	Growth hormone antagonists
EP0586549B1 (en)*	1991-05-10	2000-09-20	Genentech, Inc.	Selecting ligand agonists and antagonists
AU2147192A (en)*	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
AU7877194A (en)*	1993-09-22	1995-04-10	American Cyanamid Company	Porcine somatotropin having enhanced stability; process for producing
AU6255096A (en)*	1995-06-07	1996-12-30	Mount Sinai School Of Medicine Of The City University Of New York, The	Pegylated modified proteins
AU5881996A (en)*	1995-06-07	1996-12-30	Ohio University/Edison Biotechnology Institute	Methods of treatment using growth hormone antagonists

1996
- 1996-09-20DEDE69638117Tpatent/DE69638117D1/denot_activeExpired - Lifetime
- 1996-09-20USUS08/717,394patent/US5849535A/ennot_activeExpired - Lifetime
- 1996-09-20EPEP96931597Apatent/EP0851925B1/ennot_activeExpired - Lifetime
- 1996-09-20CACA002658039Apatent/CA2658039A1/ennot_activeAbandoned
- 1996-09-20DKDK96931597Tpatent/DK0851925T3/daactive
- 1996-09-20PTPT05007536Tpatent/PT1568772E/ptunknown
- 1996-09-20ESES05007536Tpatent/ES2338431T3/esnot_activeExpired - Lifetime
- 1996-09-20ATAT05007536Tpatent/ATE455171T1/deactive
- 1996-09-20WOPCT/US1996/014830patent/WO1997011178A1/enactiveIP Right Grant
- 1996-09-20DEDE0851925Tpatent/DE851925T1/deactivePending
- 1996-09-20DEDE69635026Tpatent/DE69635026T2/denot_activeExpired - Lifetime
- 1996-09-20EPEP05007535Apatent/EP1568771A3/ennot_activeWithdrawn
- 1996-09-20AUAU70733/96Apatent/AU718439B2/ennot_activeCeased
- 1996-09-20ESES96931597Tpatent/ES2190388T3/esnot_activeExpired - Lifetime
- 1996-09-20ATAT96931597Tpatent/ATE301196T1/deactive
- 1996-09-20DEDE1996635026patent/DE122006000003I1/deactivePending
- 1996-09-20JPJP51281497Apatent/JP3628333B2/janot_activeExpired - Fee Related
- 1996-09-20DEDE122006000003Cpatent/DE122006000003I2/deactiveActive
- 1996-09-20CACA002230492Apatent/CA2230492C/ennot_activeExpired - Lifetime
- 1996-09-20EPEP05007536Apatent/EP1568772B1/ennot_activeExpired - Lifetime
- 1996-09-20DKDK05007536.5Tpatent/DK1568772T3/daactive
1998
- 1998-02-24USUS09/028,648patent/US6004931A/ennot_activeExpired - Lifetime
- 1998-02-24USUS09/028,587patent/US6057292A/ennot_activeExpired - Lifetime
- 1998-02-24USUS09/028,652patent/US6136563A/ennot_activeExpired - Lifetime
- 1998-12-17HKHK98113801Apatent/HK1012508A1/xxnot_activeIP Right Cessation
2004
- 2004-04-21JPJP2004126082Apatent/JP3693668B2/janot_activeExpired - Lifetime
2005
- 2005-10-28LULU91204Cpatent/LU91204I2/frunknown
- 2005-11-30NLNL300210Cpatent/NL300210I2/nlunknown

Publication number	Publication date
WO1997011178A1 (en)	1997-03-27
EP1568772B1 (en)	2010-01-13
ATE301196T1 (de)	2005-08-15
US5849535A (en)	1998-12-15
DK0851925T3 (da)	2005-11-28
ES2190388T3 (es)	2006-04-01
EP1568771A3 (en)	2006-05-17
AU7073396A (en)	1997-04-09
ES2338431T3 (es)	2010-05-07
NL300210I1 (nl)	2006-02-01
LU91204I2 (fr)	2006-02-06
DE851925T1 (de)	2003-08-14
DE122006000003I2 (de)	2011-01-13
DE69635026T2 (de)	2006-05-24
JP2005021157A (ja)	2005-01-27
EP1568771A2 (en)	2005-08-31
JP3693668B2 (ja)	2005-09-07
EP1568772A3 (en)	2006-05-17
US6057292A (en)	2000-05-02
ES2190388T1 (es)	2003-08-01
DE69635026D1 (de)	2005-09-08
DE122006000003I1 (de)	2006-05-04
AU718439B2 (en)	2000-04-13
CA2230492C (en)	2009-05-26
JP3628333B2 (ja)	2005-03-09
EP0851925B1 (en)	2005-08-03
CA2658039A1 (en)	1997-03-27
HK1012508A1 (en)	1999-08-06
PT1568772E (pt)	2010-04-14
CA2230492A1 (en)	1997-03-27
US6136563A (en)	2000-10-24
NL300210I2 (nl)	2007-05-01
EP0851925A1 (en)	1998-07-08
US6004931A (en)	1999-12-21
JPH11512298A (ja)	1999-10-26
DE69638117D1 (de)	2010-03-04
ATE455171T1 (de)	2010-01-15
EP1568772A2 (en)	2005-08-31

Publication	Publication Date	Title
DK1568772T3 (da)	2010-10-18	Varianter af humant væksthormon
ES2063278T3 (es)	1995-01-01	Proteina morfogenetica de hueso.
IL149459A0 (en)	2002-11-10	Recombinant gelatins
PE14199A1 (es)	1999-02-12	Agonistas de 5-ht1f
PT934325E (pt)	2004-10-29	Trisanidridos biciclicos de tetrafosfonato
ATE186736T1 (de)	1999-12-15	Aza-zyklohexapeptide
ATE239789T1 (de)	2003-05-15	Chimäre prokoagulierende proteine
ID25478A (id)	2000-10-05	Agonis 5-ht1f
BR9307097A (pt)	1999-03-30	Composição polimérica flexível e isenta de halogênio
DK598687A (da)	1988-05-14	Detergentkomposition
BR9704377A (pt)	1999-06-01	Composições de borracha contendo n,n'-bis (hidroxifenil) maleamida
JO1999B1 (en)	1999-05-15	Isotopes of the hormone 'LH-RH' have their uses and the chemical compounds they contain
BR9710992A (pt)	2000-10-24	Derivados anticovulsivos úteis no tratamento de psorìase
BR9902081A (pt)	2002-07-23	Combinação de dofetilida e um bloqueador dos canais de cálcio
ITPD960085A0 (it)	1996-04-05	Pattini da neve con possibilita' di regolazione istantanea della velocita' utilizzabili anche come racchette da neve.
IT8682573A0 (it)	1986-09-08	Dispositivo di regolazione dell'appoggio tibiale, particolarmente per scarponi da sci.

Movatterモバイル変換

DK1568772T3 - Varianter af humant væksthormon - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=27065361

Family Applications (2)

Family Applications Before (1)

Country Status (14)

Families Citing this family (220)

Family Cites Families (26)

Also Published As

Similar Documents